Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | +16.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | +16.09% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management remains focused on their development programs and is optimistic about future prospects. However, they acknowledged the need for continued diligence.
Management highlighted ongoing efforts to advance their pipeline.
They expressed confidence in their long-term strategy despite current challenges.
Nektar Therapeutics reported a larger-than-expected loss per share, which was a positive surprise compared to analysts' expectations. However, the lack of revenue figures and guidance led to a slight decline in stock price by 1.12%. Investors may be cautious as the company navigates its development pipeline without clear financial forecasts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Aug 1, 2022